The Hawai'i Cancer Consortium, led by the University of Hawai'i Cancer Center, currently provides clinical trial access to two-thirds of cancer cases across the Hawaiian islands, aiming to expand coverage to 90%.

A quality improvement study of 560 patient encounters demonstrated that reflexology reduced stress by 40% and pain by 24% in breast cancer patients receiving radiotherapy treatment.

The 340B Drug Pricing Program has expanded from 1,000 covered entities in 1992 to over 50,000 in 2021, with hospitals marking up oncology drugs by nearly 5 times their acquisition costs.

Dr. Margaret Shipp, chief of Hematologic Neoplasia at Dana-Farber Cancer Institute, has been named the 2024 Giant of Cancer Care in lymphoma for her groundbreaking research and contributions to the field.

A Yale-led study uncovers persistent disparities in post-mastectomy care among women of color, highlighting cultural stigma as a significant barrier to breast cancer screening and treatment.

Dr. Christopher Logothetis, a distinguished professor at MD Anderson Cancer Center, has dedicated nearly 50 years to advancing genitourinary cancer treatment through groundbreaking clinical trials and personalized therapy approaches.

Current cancer drug dosing strategies based on maximum tolerated dose (MTD) may not be optimal for modern treatments, requiring a fundamental reassessment of dosing approaches in oncology.

Lixte Biotechnology is advancing LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor, for multiple cancer indications including soft tissue sarcoma and glioblastoma multiforme.

Dr. Ching Pui's groundbreaking research at St. Jude Children's Research Hospital has dramatically improved pediatric ALL survival rates from 40% to 94% through innovative treatment protocols and minimal residual disease-directed therapy.

Drug repurposing efforts demonstrate significant potential to reduce development timelines by 3-12 years, with established medications like ivermectin showing promising anti-cancer properties and methylene blue proving effective against Lyme disease.

Tyra Biosciences' oral FGFR3 inhibitor TYRA-300 is advancing in development for metastatic urothelial carcinoma and other solid tumors, with projected annual revenue of $63 million by 2036.

The USPSTF has updated breast cancer screening recommendations, now advising biennial mammograms for women aged 40-74, with personalized decisions for those 75 and older.

Non-small cell lung cancer affects approximately 2.1 million people globally, with the Asia-Pacific region showing the highest incidence and leading clinical trial activities.

The 10th Annual School of Gastrointestinal Oncology (SOGO) meeting will convene multidisciplinary experts to discuss advanced technologies and precision medicine approaches in GI cancers on February 15, 2025.

A new study reveals that IBD patients who received two doses of Shingrix vaccine showed significantly lower shingles risk (1.09%) compared to unvaccinated controls (2.4%).

Early-stage HR+/HER2- breast cancer patients face significant recurrence risks even with limited or no lymph node involvement, requiring careful evaluation of multiple risk factors beyond nodal status.

Patients with PPP2R1A-mutated endometrial cancer showed significantly improved survival on lenvatinib-pembrolizumab combination therapy compared to those with wild-type PPP2R1A.

Scientists at UCSD have identified ADAR1p150 as a key target in cancer progression, discovering its role in activating cancer stem cells and enabling immune system evasion across 20 different cancer types.

A comprehensive study of 44,992 individuals reveals that fasting plasma glucose levels, even within normal range, significantly influence diabetes risk, with a 12.8% cumulative 10-year incidence rate.

The BRIDGE clinical trial demonstrated that an AI-enabled chatbot was equally effective as standard-of-care approaches in helping eligible individuals complete cancer genetic testing, with completion rates of 12.3% versus 13.6% respectively.